Marex Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.9M Sell
703,501
-302,212
-30% -$14.3M 0.16% 115
2025
Q4
$51.2M Buy
1,005,713
+355,973
+55% +$18.2M 0.32% 77
2025
Q3
$36.1M Buy
649,740
+468,674
+259% +$27.4M 0.25% 78
2025
Q2
$12.5M Buy
181,066
+108,883
+151% +$7.41M 0.11% 122
2025
Q1
$5.01M Buy
72,183
+21,236
+42% +$1.75M 0.1% 105
2024
Q4
$4.38M Buy
50,947
+44,947
+749% +$4.86M 0.07% 102
2024
Q3
$714K Sell
6,000
-6,811
-53% -$908K 0.02% 251
2024
Q2
$1.83M Buy
+12,811
New +$1.7M 0.05% 166

Other funds holding NVO

Marex Group's NVO Position: Q1 2026 in Review

Marex Group reduced its Novo Nordisk (NVO) stake by 30% in Q1 2026, selling an estimated $14.3M and leaving 703,501 shares worth $25.9M. The position accounts for 0.16% of the portfolio, ranked #115.

Marex Group first reported a position in NVO in Q2 2024 and has held it in 8 quarters since. The position peaked at $51.2M in Q4 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Marex Group held 703,501 shares of Novo Nordisk worth $25.9M as of Q1 2026.
  • Marex Group sold 302,212 Novo Nordisk shares in Q1 2026, an estimated $14.3M.
  • Novo Nordisk made up 0.16% of Marex Group's portfolio in Q1 2026, its #115 holding.
  • Marex Group first reported a position in Novo Nordisk in Q2 2024 and has held it in 8 quarters since.
  • Marex Group's Novo Nordisk position peaked at $51.2M in Q4 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.